Free Trial

Wave Life Sciences Q2 2023 Earnings Report

Wave Life Sciences logo
$13.51 +0.32 (+2.43%)
(As of 12/20/2024 05:31 PM ET)

Wave Life Sciences EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Wave Life Sciences Revenue Results

Actual Revenue
$22.11 million
Expected Revenue
$8.08 million
Beat/Miss
Beat by +$14.03 million
YoY Revenue Growth
N/A

Wave Life Sciences Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)

I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.

Click here to see the details because I believe a lot of people will get rich.

Wave Life Sciences Earnings Headlines

Brokerages Set Wave Life Sciences Ltd. (NASDAQ:WVE) PT at $22.22
Cackling Kamala hates this company
Do you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution.
Wave Life Sciences price target raised to $22 from $19 at Mizuho
See More Wave Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Wave Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Wave Life Sciences and other key companies, straight to your email.

About Wave Life Sciences

Wave Life Sciences (NASDAQ:WVE), a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

View Wave Life Sciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings